Have £2,000 to invest in the FTSE 100? I’d buy these 2 bargain income stocks today

These two FTSE 100 (INDEXFTSE:UKX) dividend shares could deliver high returns in my opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The uncertain outlook for the UK economy could mean that interest rates remain at a low level for some time. In fact, there are rumours that the next move for interest rates could be downwards, with the Bank of England apparently becoming increasingly dovish as the prospects for the world economy remain challenging.

This could mean that dividend stocks offer increasingly appealing outlooks when compared to other mainstream assets. As such, now could be the right time to buy these two FTSE 100 income shares. They may deliver high income returns, as well as capital growth, over the long run.

GSK

The outlook for GSK (LSE: GSK) and the wider pharmaceuticals industry could improve significantly over the long run. Demand for healthcare-related products and services may rise due to an ageing global population, which could mean that the company’s decision to focus on its pharmaceutical operations leads to an improving rate of profit growth.

However, an improving financial outlook may take time to achieve. In the current year, GSK is forecast to post a fall in earnings of 3%, while growth of 2% in the next financial year may mean that investors struggle to become increasingly bullish about the stock from a growth perspective over the near term.

Of course, its defensive characteristics may boost its appeal in the short run. GSK’s lack of dependence on the wider economy for its growth could lead to increasing demand among investors who could become increasingly risk-averse. Since it offers a dividend yield of around 4.6%, its total returns may therefore be highly attractive.

As such, now could be a good time to buy the stock, with its income prospects, defensive appeal and long-term growth potential suggesting that it may outperform the FTSE 100.

Rio Tinto

Unlike GSK, FTSE 100 index peer Rio Tinto (LSE: RIO) lacks defensive appeal. Its financial performance is closely linked to the prospects for the world economy. Since there are concerns surrounding the outlook for China due in part to the global trade war, it would be unsurprising for the stock’s valuation to come under a degree of pressure in the near term.

However, Rio Tinto’s current valuation suggests that investors may have factored in many of the risks facing the business. It currently trades on a price-to-earnings (P/E) ratio of just 8, which indicates that it has a wide margin of safety. With the company having a relatively low level of gearing, it could prove to be more resilient than some of its sector peers should the performance of the world economy disappoint.

The stock’s dividend yield of 6.9% suggests that it could offer income investing potential over the long run. While there may be more stable income opportunities elsewhere in the FTSE 100, the iron ore miner may be able to produce a high overall return for patient investors.

Peter Stephens owns shares of GlaxoSmithKline and Rio Tinto. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »